Dr. Julie-An Talano
Claim this profileMedical College of Wisconsin
Studies Lymphoid Leukemia
Studies Acute Lymphoblastic Leukemia
9 reported clinical trials
17 drugs studied
Area of expertise
1Lymphoid Leukemia
CD19 positive
CD20 positive
2Acute Lymphoblastic Leukemia
CD19 positive
CD20 positive
Affiliated Hospitals
Clinical Trials Julie-An Talano is currently running
Stem Cell Transplant Conditioning
for SCID
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants. The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.
Recruiting1 award Phase 244 criteria
Stem Cell Transplant with Conditioning Regimen
for Blood Diseases
This phase II clinical trial studies how well treosulfan, thiotepa, fludarabine, and rabbit anti-thymocyte globulin (rATG) before donor stem cell transplantation works in treating patients with nonmalignant (non-cancerous) diseases. Hematopoietic cell transplantation has been shown to be curative for many patients with nonmalignant (non-cancerous) diseases such as primary immunodeficiency disorders, immune dysregulatory disorders, hemophagocytic lymphohistiocytosis, bone marrow failure syndromes, and hemoglobinopathies. Powerful chemotherapy drugs are often used to condition the patient before infusion of the new healthy donor cells. The purpose of the conditioning therapy is to destroy the patient's abnormal bone marrow which doesn't work properly in order to make way for the new healthy donor cells which functions normally. Although effective in curing the patient's disease, many hematopoietic cell transplantation regimens use intensive chemotherapy which can be quite toxic, have significant side effects, and can potentially be life-threatening. Investigators are investigating whether a new conditioning regimen that uses less intensive drugs (treosulfan, thiotepa, and fludarabine phosphate) results in new blood-forming cells (engraftment) of the new donor cells without increased toxicities in patients with nonmalignant (non-cancerous) diseases.
Recruiting1 award Phase 28 criteria
More about Julie-An Talano
Clinical Trial Related5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Julie-An Talano has experience with
- Tisagenlecleucel
- CliniMACS
- Peripheral Blood Stem Cell Transplantation
- Etoposide
- Dexamethasone
- Ruxolitinib
Breakdown of trials Julie-An Talano has run
Lymphoid Leukemia
Acute Lymphoblastic Leukemia
T-Lymphoblastic Leukemia/Lymphoma
Uterine Tumors
Hematological Malignancies
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Julie-An Talano specialize in?
Julie-An Talano focuses on Lymphoid Leukemia and Acute Lymphoblastic Leukemia. In particular, much of their work with Lymphoid Leukemia has involved CD19 positive patients, or patients who are CD20 positive.
Is Julie-An Talano currently recruiting for clinical trials?
Yes, Julie-An Talano is currently recruiting for 3 clinical trials in Milwaukee Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Julie-An Talano has studied deeply?
Yes, Julie-An Talano has studied treatments such as Tisagenlecleucel, CliniMACS, Peripheral Blood Stem Cell Transplantation.
What is the best way to schedule an appointment with Julie-An Talano?
Apply for one of the trials that Julie-An Talano is conducting.
What is the office address of Julie-An Talano?
The office of Julie-An Talano is located at: Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States. This is the address for their practice at the Medical College of Wisconsin.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.